Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132193 | 1.00 | CA1 (0.50) | CA1CA14TDP1HPGDTSHR | |
| SCHEMBL1758631 | 0.83 | MEN1 (0.50) | TDP1HPGDMCL1ALDH1A1POLB | |
| SCHEMBL13044533 | 0.81 | ALDH1A1 (0.48) | CA1TDP1HPGDTSHRRAB9A | |
| SCHEMBL3132943 | 0.79 | KMT2A (0.47) | CA1TDP1HPGDTSHRRAB9A | |
| SCHEMBL29062573 | 0.79 | ERN1 (0.52) | CA1CA14TDP1HPGDTSHR | |
| SCHEMBL24427676 | 0.79 | CXCR2 (0.38) | CA1CA14TDP1HPGDTSHR | |
| SCHEMBL7529692 | 0.79 | MAPK1 (0.50) | TDP1RAB9AALDH1A1NPC1POLB | |
| SCHEMBL7531866 | 0.79 | HTT (0.46) | RAB9AALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL14855436 | 0.79 | KMT2A (0.43) | POLBKMT2ANPSR1 | |
| SCHEMBL2088762 | 0.79 | RAB9A (0.46) | HPGDRAB9AALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2636669-B1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF AS FUNGICIDE | SINOCHEM CORP (CN) | 2015-10-21 | — | — | EP | claimed |
| US-8614214-B2 | Pyrazole amide compounds and uses thereof | SINOCHEM CORPORATION (CN) | 2013-12-24 | — | — | US | claimed |
| EP-2636669-A1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF | Sinochem Corporation (CN) | 2013-09-11 | — | — | EP | claimed |
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-08-29 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| CN-110579936-B | Thermally developable photosensitive material and medical film using the same | 柯尼卡美能达株式会社 | 2023-10-27 | — | — | CN | disclosed |
| CN-115850123-A | Preparation method of 2, 4-dichloroaniline/hydrazine | 山东潍坊润丰化工股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0362808-A2 | Silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0073404-B1 | PROCESS FOR MAKING ARYLISOCYANIDE DICHLORIDES | CASSELLA Aktiengesellschaft (DE) | 1984-12-27 | — | — | EP | disclosed |
| US-4401603-A | CHLORINATION OF THE SOLUTION OR SUSPENSION FORMED BY THE FORMYLATION OF AN ARYLAMINE IN A SOLVENT | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-08-30 | — | — | US | disclosed |
| EP-0073404-A1 | Process for making arylisocyanide dichlorides | CASSELLA Aktiengesellschaft (DE) | 1983-03-09 | — | — | EP | disclosed |
| US-4262005-A | CONTROLLING ECTOPARASITES WHICH ATTACK CATTLE AND PIGS | THE BOOTS COMPANY LIMITED (GB) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | BROX, OAT, CAT | CA1 2739/4885CA14 4237/4885TDP1 4236/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | CA1 4153/4885CA14 4378/4885TDP1 498/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | CA1 4153/4885CA14 4378/4885TDP1 498/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | CA1 4153/4885CA14 4378/4885TDP1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.